Trump seeking economic deal with China as fresh trade talks loom- WSJ
MIAMI - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotech company with a current market capitalization of $36 million, announced Friday that its lead compound Telomir-1 demonstrated superior ability to reverse epigenetic gene silencing in aggressive prostate cancer cells compared to established drugs Paclitaxel and Rapamycin. According to InvestingPro data, while the company’s stock has declined 74% over the past six months, analysts maintain an optimistic price target of $15.50 per share.
In preclinical research using human prostate cancer cell models, Telomir-1 fully reversed the hypermethylation of STAT1, a key immune regulator frequently suppressed in advanced cancers. The study showed Telomir-1 administered orally over 21 days in a mouse model with implanted PC3 human prostate cancer cells achieved complete reversal of this hypermethylation, while Paclitaxel showed no effect and Rapamycin achieved only partial reduction.
"This study provides novel and direct molecular evidence of Telomir-1’s ability to reprogram cancer epigenetics," said Erez Aminov, CEO of Telomir, according to the company’s press release.
The research also found Telomir-1 reduced hypermethylation of TMS1, another tumor suppressor commonly silenced in prostate cancer. Importantly, the compound did not elongate telomeres in the cancerous prostate cells, which the company states reinforces its safety profile.
These findings build on previously announced results from March 19, 2025, where Telomir-1 was reported to reduce tumor volume by approximately 50% when combined with Paclitaxel in the same prostate cancer model.
Telomir is conducting ongoing research to evaluate Telomir-1 across multiple therapeutic areas, including oncology, Wilson’s disease, age-related macular degeneration, autism spectrum disorder, and dysphonia.
The company is continuing preclinical development and plans to announce its initial IND indication at a future date, according to the press release statement. InvestingPro analysis indicates the company currently operates with a moderate debt level and faces challenges with short-term obligations exceeding liquid assets, highlighting the importance of successful clinical developments. InvestingPro subscribers have access to 8 additional key insights about Telomir’s financial health and market position.
In other recent news, Telomir Pharmaceuticals has announced significant findings from multiple preclinical studies involving its lead drug candidate, Telomir-1. The company reported positive preclinical data in human progeria cell lines, showcasing Telomir-1’s ability to improve cell viability, reduce oxidative stress, and restore mitochondrial function. These promising results were observed in cells from children with Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder. Additionally, Telomir-1 showed potential in treating Wilson’s disease by improving neurological, liver, and kidney functions in an animal model, suggesting a disease-modifying approach. The study highlighted improvements in liver biomarkers and reduced copper accumulation, which are critical in managing Wilson’s disease. In another study, Telomir-1 demonstrated its effectiveness in reversing key aging markers in an animal model of Werner Syndrome, a disorder associated with accelerated aging. These findings further support Telomir Pharmaceuticals’ plans to advance Telomir-1 through Investigational New Drug (IND) applications and potential clinical trials. The company is actively exploring regulatory pathways, including orphan drug designation, as it evaluates rare disease indications for initial clinical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.